Prof Siow Ming Lee presents IPSOS, a phase 3 study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC - not eligible for a platinum-containing regimen. 

The results of trial showed 1L atezo improved OS vs chemo in platinum-ineligible pts with NSCLC, with twice as many pts estimated to be alive at 2 yr when treated with atezo vs chemo. Additionally, no new or unexpected safety concerns were seen in this poor prognosis population.